We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 1.83% | 27.75 | 27.50 | 28.00 | 27.75 | 27.25 | 27.25 | 1,058,943 | 14:49:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 56.04M | 16.12M | 0.0237 | 11.65 | 185.4M |
From Jul 2019 to Jul 2024
TIDMVENN
RNS Number : 8246C
Venn Life Sciences Holdings PLC
30 June 2016
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Result of AGM
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that at its Annual General Meeting held earlier today, all resolutions were duly passed.
Enquiries:
Venn Life Sciences Holdings Plc www.vennlifesciences.com Tony Richardson, Chief Executive Officer Tel: +353 154 99 341 Jonathan Hartshorn, Chief Financial Officer Tel: +353 153 93 269 Aoife O Farrell, Marketing Manager Tel: +353 153 93 269 Davy (Nominated Adviser, ESM Adviser and Tel: +353 1 679 6363 Joint Broker) Fergal Meegan / Matthew DeVere White (Corporate Finance) Paul Burke (Corporate Broking) Hybridan LLP (Joint-Broker) Claire Louise Noyce Tel: 020 3764 2341 Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com Paul McManus Mob: 07980 541 893 Lianne Cawthorne Mob: 07584 391 303
About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
For more information about the Company, please visit: www.vennlifesciences.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGURAARNNANOAR
(END) Dow Jones Newswires
June 30, 2016 07:18 ET (11:18 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
